Metro Infectious Disease Consultants
Decatur, Georgia, United States
Disclosure(s): AbbVie: Grant/Research Support; Gilead Sciences, Inc.: Grant/Research Support; ViiV: Advisor/Consultant, Grant/Research Support
577 - Week 48 Results of a Phase 2 Study Evaluating Once-weekly Oral Islatravir Plus Lenacapavir
Saturday, October 19, 2024
2:09 PM – 2:21 PM US PT